NCT02109146View on ClinicalTrials.gov

Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma

PHASE3CompletedINTERVENTIONAL
Enrollment

332

Participants

Timeline

Start Date

March 26, 2014

Primary Completion Date

May 13, 2023

Study Completion Date

May 13, 2023

Conditions
Hepatocellular CarcinomaTranscatheter Arterial Chemoembolization
Interventions
DRUG

Prophylactic Transcatheter Arterial Chemoembolization

Participants enrolled in the adjuvant TACE group received one to two cycles of TACE with an interval of 4\~6 weeks, and the first TACE was given within 1 week after randomization.

OTHER

Observation

Participants enrolled in the observation group were subjected to active surveillance without any adjuvant treatment.

Trial Locations (1)

310000

The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Zhejiang University

OTHER

NCT02109146 - Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter